Moderate To Severe Plaque Psoriasis Pipeline Outlook 2025: Insights Into Therapies, Research, And Market Potential

DelveInsight's, “Moderate To Severe Plaque Psoriasis Pipeline Insight 2025” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Moderate To Severe Plaque Psoriasis pipeline landscape. It covers the Moderate to Severe Plaque Psoriasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Moderate to Severe Plaque Psoriasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Moderate to Severe Plaque Psoriasis Pipeline? Click here to explore the therapies and trials making headlines @ Moderate to Severe Plaque Psoriasis Pipeline Outlook Report

Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report

• On 04 September 2025, Alumis Inc. announced a study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study.
• On 02 September 2025, Bristol-Myers Squibb conducted a study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis.
• DelveInsight's Moderate to Severe Plaque Psoriasis Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Moderate to Severe Plaque Psoriasis treatment.
• The leading Moderate to Severe Plaque Psoriasis Companies such as Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Jansen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.
• Promising Moderate to Severe Plaque Psoriasis Therapies such as Bimekizumab, Ustekinumab, Adalimumab, KHK4827, ABT-874, Etanercept, MSB11022, CT-P17 and others.

Want to know which companies are leading innovation in Moderate to Severe Plaque Psoriasis? Dive into the full pipeline insights @ Moderate to Severe Plaque Psoriasis Clinical Trials Assessment

The Moderate to Severe Plaque Psoriasis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Moderate to Severe Plaque Psoriasis Pipeline Report also highlights the unmet needs with respect to Moderate to Severe Plaque Psoriasis.

Moderate to Severe Plaque Psoriasis Overview

Moderate to Severe Plaque Psoriasis is the most common type of psoriasis. Those thick, scaly patches that develop on the skin are called plaques (placks). About 80% to 90% of people living with psoriasis get plaques, so they have plaque (plack) psoriasis. It is an autoimmune disease in which skin cells rapidly build up, forming scales and dry, itchy patches that flake off. Scientists don't yet fully understand the mechanisms behind autoimmune diseases like Moderate to Severe Plaque Psoriasis, but it is believed that a person's genetics play a central role.

Moderate to Severe Plaque Psoriasis Emerging Drugs

• BMS-986165 : Bristol-Myers Squibb

Deucravacitinib (BMS-986165) is a first-in-class, oral, selective tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action. Deucravacitinib is the first and only TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed deucravacitinib to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-12, IL-23 and Type 1 interferon (IFN), key cytokines involved in psoriasis pathogenesis. Due to the innovative design of deucravacitinib, Bristol Myers Squibb earned recognition with the 2019 Thomas Alva Edison Patent Award for the science underpinning the clinical development of deucravacitinib. Deucravacitinib is being studied in multiple immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus and inflammatory bowel disease.

• AK111: Akeso Biopharma

AK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Moderate to Severe Plaque Psoriasis.

If you're tracking ongoing Moderate to Severe Plaque Psoriasis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Moderate to Severe Plaque Psoriasis Treatment Drugs

The Moderate to Severe Plaque Psoriasis Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Moderate to Severe Plaque Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Moderate to Severe Plaque Psoriasis Treatment.
• Moderate to Severe Plaque Psoriasis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Moderate to Severe Plaque Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Moderate to Severe Plaque Psoriasis market.

Moderate to Severe Plaque Psoriasis Companies

Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Jansen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.

Moderate to Severe Plaque Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Moderate to Severe Plaque Psoriasis Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

From emerging drug candidates to competitive intelligence, the Moderate to Severe Plaque Psoriasis Pipeline Report covers it all – check it out now @ Moderate to Severe Plaque Psoriasis Market Drivers and Barriers, and Future Perspectives

Scope of the Moderate to Severe Plaque Psoriasis Pipeline Report

• Coverage- Global
• Moderate to Severe Plaque Psoriasis Companies- Bristol-Myers Squibb, Akeso Biopharma, Jiangsu Hengrui Medicine, Nimbus Therapeutics, Sun Pharmaceutical Industries Limited, Suzhou Zelgen Biopharmaceuticals, GC Cell Corporation, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite Biopharma, Bio-thera Solutions, AbbVie, Sinocelltech, Jansen Research and Development, Innovent Biologics, Aurigene Discovery, Affibody, GlaxoSmithKline, Abcentra and others.
• Moderate to Severe Plaque Psoriasis Therapies- Bimekizumab, Ustekinumab, Adalimumab, KHK4827, ABT-874, Etanercept, MSB11022, CT-P17 and others.
• Moderate to Severe Plaque Psoriasis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Moderate to Severe Plaque Psoriasis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what's next for the Moderate to Severe Plaque Psoriasis treatment landscape in this detailed analysis @ Moderate to Severe Plaque Psoriasis Emerging Drugs and Major Players

Table of Contents